Advanced Renal Cell Carcinoma

Beyond LAG-3: Promising Immuno-Oncology Targets in Kidney Cancer
Katy Beckermann, MD, PhD, of Vanderbilt-Ingram Cancer Center, and Michael Atkins, MD, of Georgetown Lombardi Comprehensive Cancer Center, weigh the potential of targeting T regulatory cells (Tregs) in kidney cancer treatment, particularly in relation to PD-1 therapy. Dr. Atkins highlights ongoing research into CTLA-4 antibodies that deplete Tregs and their potential to enhance response rates when combined with anti-PD-1 therapy. ...
Advertisement

Latest News

Advertisement

Knowledge Hub Spotlights

Curated clinical content based on conditions, therapies, and technologies

Renal Cell Carcinoma
Renal Cell Carcinoma

Conference Coverage

Advertisement
Section Editor

Advertisement
Get the latest RCC research straight to your inbox.